BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of [125I]-recombinant human interleukin-11: 2. Placental transfer and excretion into milk after subcutaneous administration to rats. 1998

T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
Drug Metabolism Laboratories, Yamanouchi Pharmaceutical Co. Ltd, Tokyo, Japan.

Placental transfer and excretion into milk of [125I]-rhIL-11 (recombinant human interleukin-11) after subcutaneous administration in female rats were investigated. After administration of [125I]-rhIL-11 to rats on the 14th day of gestation, radioactivity in the kidney was the highest among excised tissues, being 3 times higher than that in the plasma at 1.5 h. Radioactivity in other tissues, including the mammary gland, ovary, uterus, placenta and amniotic fluid, was lower than that in the plasma. Although radioactivity in fetuses was detected 6 h after administration, the level was only 2% of the plasma concentration in dams, and the radioactivity was not found in fetal-derived TCA precipitates. These results indicate that rhIL-11 does not readily pass through the placenta into the fetus. After subcutaneous administration of [125I]-rhIL-11 to lactating rats 14 days after delivery, radioactivity in milk was 1.1-1.6 times that in the plasma of dams. Radioactivity in clotted milk in the stomachs of suckling infants was almost equal to that in the dam's milk; however, only a small amount of radioactivity was detected in infant kidneys.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007774 Lactation The processes of milk secretion by the maternal MAMMARY GLANDS after PARTURITION. The proliferation of the mammary glandular tissue, milk synthesis, and milk expulsion or let down are regulated by the interactions of several hormones including ESTRADIOL; PROGESTERONE; PROLACTIN; and OXYTOCIN. Lactation, Prolonged,Milk Secretion,Lactations, Prolonged,Milk Secretions,Prolonged Lactation,Prolonged Lactations
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D010920 Placenta A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES). Placentoma, Normal,Placentome,Placentas,Placentomes
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer.
August 1989, Journal of biological response modifiers,
T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
Biodistribution and pharmacokinetics of recombinant, human 125I-interleukin-2 in mice.
January 1989, International journal of immunopharmacology,
T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
Nadolol: placental transfer and excretion in the milk of rats.
February 1977, Toxicology and applied pharmacology,
T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.
June 1990, British journal of clinical pharmacology,
T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
Pharmacokinetics of Ketamine Transfer Into Human Milk.
January 2023, Journal of clinical psychopharmacology,
T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
[Pharmacokinetics and toxicity of intrathecal administration of recombinant interleukin 2].
July 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits.
January 2018, Drug design, development and therapy,
T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers.
April 1998, British journal of clinical pharmacology,
T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
May 1999, European journal of neurology,
T Uchida, and K Aoyama, and K Mori, and T Usui, and T Watanabe, and Y Takariki, and N Asahara, and M Hirose, and T Kimura, and M Tateishi, and S Higuchi
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
March 1998, European journal of neurology,
Copied contents to your clipboard!